Matinas BioPharma Holdings, Inc. (MTNB) is a Healthcare stock trading at $0.20 (as of 2026-08-21), with a market capitalization of $1.26M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company developing product candidates using its lipid nanocrystal (LNC) delivery platform. Its pipeline includes LYPDISO and other prescription medicines being studied for conditions such as cardiovascular/metabolic disorders and prevention or treatment of fungal and multidrug-resistant bacterial infections.
Matinas BioPharma is a clinical-stage biopharmaceutical company that develops product candidates using its lipid nanocrystal (LNC) delivery platform, including LYPDISO (a prescription-only omega-3 free fatty acid-based composition), and its financial outcome depends on how successfully these candidates progress toward prescription use.
As a clinical-stage biopharma, Matinas' profit model is primarily determined by pipeline progress, where its LNC platform supports the development of product candidates like LYPDISO that must advance to prescription commercialization.
Business quality (Weak): Based on the provided facts, the company’s core narrative centers on its LNC platform and lead candidate LYPDISO, but there are no disclosed reportable segments or operating KPIs available in the data provided.
| Price | $0.20 |
| Market Cap | $1.26M |
| Price / Book | 0.70 |
| Revenue (TTM) | $1.10M |
| Net Margin | -2093.2% |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | NORTHERN TRUST CORP ($42703.00) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Jerome D. Jabbour |
| Employees | 3 |
| Country | US |
| IPO Date | 2014-07-21 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.